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Background and aims: Interventions to improve adherence to medication may be more 2 
effective if tailored to the individual, addressing adherence-related beliefs about treatment 3 
and overcoming practical barriers to daily use.  We evaluated whether an algorithm tailoring 4 
support to address perceptual and practical barriers to adherence reduced barriers and was 5 
acceptable to patients with IBD. 6 
Methods: Participants with IBD, prescribed azathioprine and/or mesalazine were recruited via 7 
patient groups, social media and hospital clinics and allocated to Intervention or Control 8 
Groups. The online intervention comprised messages tailored to address beliefs about IBD 9 
and maintenance treatment and provide advice on overcoming practical difficulties with 10 
taking regular medication. The content was personalised to address specific perceptual and 11 
practical barriers identified by a pre-screening tool. Validated questionnaires assessed 12 
barriers to adherence and related secondary outcomes at baseline, one and three months of 13 
follow-up.  14 
Results: 329 participants were allocated to the Intervention (n=153) and Control (n=176) 15 
Groups; just under half (46.2%) completed follow-up. At one and three months the 16 
Intervention Group had significantly fewer concerns about IBD medication (p≤.01); and, at 17 
three months only, fewer doubts about treatment need, fewer reported practical barriers and 18 
lower nonadherence (p<.05). Relative to controls at follow-up, the Intervention Group were 19 
more satisfied with information about IBD medicines, and viewed pharmaceuticals in general 20 
more positively. Questionnaires, interviews and intervention usage indicated the intervention 21 
was acceptable. 22 
Conclusions: Personalised adherence support using a digital algorithm can help patients 23 
overcome perceptual (doubts about treatment necessity and medication concerns) and 24 
practical barriers to adherence. 25 
Keywords: Medication nonadherence; inflammatory bowel disease; digital intervention, 26 
Necessity Concerns Framework. 27 
 28 
  29 
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Personalised adherence support for maintenance treatment of inflammatory bowel 1 
disease: A tailored digital intervention to change adherence-related beliefs and barriers 2 
Inflammatory bowel disease (IBD), comprising ulcerative colitis and Crohn’s disease, is 3 
treated with maintenance drugs including mesalazine, thiopurines (e.g. azathioprine), anti-4 
TNF therapies, and anti-integrins (e.g. vedolizumab). [1] These drugs control flare-ups [2-4], 5 
avoid surgery, reduce colorectal cancer risk [1], and improve quality of life. However, an 6 
estimated 53-72% of people with IBD do not take their medication as prescribed, resulting in 7 
increased morbidity, healthcare costs, and decreased quality of life. [2, 5-10]  8 
Nonadherence to medication may be intentional and unintentional, arising from motivation 9 
and ability. [11] Motivation is influenced by factors including patients’ perceptions and 10 
experience of IBD and maintenance treatment, and trust in the prescriber and prescription. 11 
Ability is influenced by internal (e.g. physical capability to administer maintenance 12 
treatment) [11] and external (e.g. access to maintenance treatment) factors. [12] These 13 
principles are recognised in the Perceptions and Practicalities Approach (PAPA) [13] to 14 
supporting adherence, applied in NICE Medicines Adherence Guidelines. [14] This approach 15 
suggests adherence support will be more effective if it addresses both perceptions (e.g. beliefs 16 
about illness and treatment) and practicalities (e.g. capability and resources) affecting ability 17 
and motivation to adhere. The importance of addressing IBD patients’ beliefs has been 18 
highlighted in a systematic review which found judgements of personal need for maintenance 19 
medication (Necessity beliefs) and concerns about adverse consequences of treatment were 20 
key determinants of nonadherence. [15-17] The Necessity-Concerns Framework [18] states 21 
patients will be particularly motivated to take treatment when perceived personal need 22 
(Necessity beliefs) is high relative to concerns about potential side effects (Concerns beliefs). 23 
[19].  24 
Beliefs are influenced by perceptions of IBD and symptoms. Patients who see a fit between 25 
their IBD (illness representations) and their maintenance treatment are more likely to think 26 
maintenance treatment is necessary. For many patients, taking medication does not ‘make 27 
common-sense’ when they feel well. Likewise, Concerns may arise from perceiving 28 
symptoms as side effects. But, even patients who have not experienced side effects can 29 
harbour concerns e.g. about long-term effects, or dependence [20]. Such concerns have been 30 
related to suspicions of pharmaceutical treatments and general background beliefs about 31 
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medicines (e.g. that they are intrinsically harmful [20]) and to patients’ perceived personal 1 
sensitivity to medication effects.   2 
These findings suggest a three stage PAPA-based intervention may support adherence: 1) 3 
Provide a rationale for medication necessity so that patients perceive a ‘common-sense’ fit 4 
between IBD and treatment 2) elicit and address concerns about IBD medication and 3) 5 
address practical barriers to adherence.  Studies in other long-term conditions have 6 
demonstrated the efficacy of this approach in improving adherence (e.g. [21, 22]), but no 7 
interventions have incorporated this approach for IBD. 8 
We report a ‘proof of principle’ study in which we examined a PAPA-based intervention in 9 
which support was tailored to address treatment necessity beliefs and concerns and help 10 
overcome practical barriers to adherence. We used an online platform to deliver the 11 
intervention because many patients with IBD access information online and because this 12 
support could be integrated with usual clinical care but accessed at patients’ convenience.  13 
Our aims were to: 1) Develop the PAPA-based intervention and 2) Evaluate the intervention 14 
based on a) capacity to change perceptual and practical barriers to adherence; b) feasibility of 15 
delivering online; and c) acceptability to patients. 16 




In line with the objectives, this study had two phases 1) intervention development and 2) 2 
intervention pilot.  3 
Ethics and trial registration 4 
The study received ethical approved from the NRES Committee London-Central. The trial 5 
protocol was registered with a clinical trial database http://clinicaltrials.gov/ (Identifier 6 
NCT01852097).  7 
Phase 1: Intervention Development 8 
We followed the recommendations of the MRC for complex intervention development, and 9 
considered research on the determinants of a behaviour and involving patients in the 10 
intervention design [20]. As recommended by Horne and Clatworthy [23] the adherence 11 
intervention was developed considering content, context and channel (delivery vehicle). 12 
Content: Our PAPA-based intervention applied National and European guidelines for IBD 13 
management [24-31], UK adherence guidelines, [14], and research about barriers to 14 
adherence in IBD. [15] We involved advisory panels of UK IBD patients and expert 15 
clinicians to ensure that the intervention was appropriate to the local healthcare context. To 16 
enable us to provide information about the medication participants were taking, we focused 17 
on two of the most common IBD maintenance medications available in practice at the time of 18 
the study design, azathioprine and mesalamine. The intervention addressed the 3-component 19 
PAPA model: 20 
1) Necessity- Addressing doubts about need for medication 21 
2) Concerns- Addressing concerns about potential adverse effects of medication 22 
3) Practical Barriers- Addressing practical issues with taking medication in daily life 23 
We also added an IBD Library- comprising general resources about living with IBD not 24 
tailored to address medication adherence directly. 25 
Each of the three PAPA components was addressed using a number of Behaviour Change 26 
Techniques (BCTs) [32] designed to modify behaviour regulatory processes. For example, to 27 
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increase perceived need for treatment ‘Necessity’ we used the BCTs  ‘Information on health 1 
consequences’ and ‘Credible Source’, providing quotes from IBD experts to explain why 2 
patients need to take medication during both flare-ups and remission. Full details of the BCTs 3 
used in each part of the intervention and example content are presented in Supplement 1. We 4 
followed a communication strategy based on cognitive behavioural therapy and motivational 5 
interviewing, to ensure that the BCTs were delivered using language that would enhance 6 
awareness and intrinsic motivation. 7 
Channel (delivery vehicle): The content of the messages was personalised using the 8 
Persignia1 algorithm which tailors content to address specific perceptual and practical barriers 9 
identified by a pre-screening tool.  10 
Context: To assess whether the intervention content and channel would fit well with existing 11 
care pathways, we conducted three focus groups with 8 IBD patients. The Intervention 12 
Development Group (specialists in gastroenterology, clinical psychology, pharmacy, and 13 
health psychology) and three IBD patients undertook further usability testing. Further details 14 
and a sample page are presented in the Supplementary Material.  15 
Phase 2: Intervention Pilot 16 
Design 17 
The pilot was a single-blinded, quasi-randomized trial of the online intervention comparing 18 
intervention and passive control (receiving standard care) groups. Patients completed the 19 
study measures three times: baseline (immediately prior to receiving the intervention link), at 20 
1 month (30 days after starting the baseline measures, and at 3 months (90 days after starting 21 
the baseline measures). Our primary outcomes were self-reported perceptual and practical 22 
barriers (BMQ Specific Concerns, BMQ Specific Necessity, and Practical Barriers). We also 23 
tested whether the intervention had effects on a range of secondary outcomes: adherence, 24 
beliefs about medicines in general, perceived sensitivity to the effects of medicines, beliefs 25 
about IBD, satisfaction with information received about IBD medications, anxiety, 26 
depression, quality of life, reported disease activity, reported treatment seeking and reported 27 
burden of adverse effects to IBD maintenance treatment. We measured intervention usage 28 
                                                          
1 Working title 
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statistics to assess feasibility. We used post-intervention questionnaires and interviews to 1 
gauge acceptability of the intervention. 2 
Inclusion/Exclusion Criteria 3 
We recruited people aged 18 years or older, who reported a diagnosis of IBD and a current 4 
prescription of azathioprine and/or mesalamine. We planned to exclude participants who did 5 
not report at least one perceptual or practical barrier (i.e. no concerns about their medication, 6 
no doubts about their need for medication and no practical barriers in the baseline 7 
questionnaire). But all participants who entered the study reported at least one barrier. 8 
Recruitment 9 
Participants were recruited through Crohn’s and Colitis UK’s website, Facebook and Twitter 10 
accounts. We also placed leaflets and posters in IBD clinics at University College London 11 
Hospital and Brighton and Sussex University Hospitals NHS Trust. Potential participants 12 
followed a link to information about the study and an eligibility questionnaire. Eligible 13 
participants were then asked to provide informed consent. After the study commenced, we 14 
became concerned that the dropout rate was higher than expected. We introduced a prize 15 
draw for a £150 online gift voucher into which participants who completed all follow-ups 16 
would be entered. 17 
Allocation 18 
Participants were allocated to Intervention or Control Groups by a computer algorithm blind 19 
to their baseline characteristics. Due to an unanticipated technical issue this algorithm 20 
allocated slightly more participants to the Control Group than the Intervention Group as the 21 
study progressed2, and so although blind, was not fully randomized. As a result of this 22 
technical issue, 7 participants who resubmitted their baseline questionnaires (we suspect by 23 
                                                          
We planned to stratify participants by medication (azathioprine/mesalamine/both) and randomize using a 
computer generated random number sequence.  To ensure equal group numbers, this was operationalized using a 
minimization algorithm; with the first participant in each strata randomized and subsequent participants assigned 
to the group with fewest participants for their medication.  Due to an unanticipated feature of the platform, 
participants had new random allocation values encoded when completing follow-up questionnaires. These new 
allocation values, rather than original allocations, were used to randomize new participants.  More Intervention 
Group participants dropped-out, so, as the study progressed these participants had an allocation value frozen at 
Intervention, meaning subsequent allocations were more likely to be to the Control Group. Thus we did not 
randomize. However, the algorithm had no effect on the intervention content presented to participants. 
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hitting refresh mid-submission) were allocated twice at baseline and recorded on our system 1 
as allocated to both the Control and Intervention Groups. To avoid potentially cross-2 
contaminated participants, we excluded these from the analyses below. 3 
Measures 4 
Participants received the same questionnaire package at baseline, 1 and 3 months, which took 5 
approximately 25 minutes to complete. It included: 6 
Beliefs about Medicine Questionnaire (BMQ). The BMQ is a validated scale [29] with two 7 
parts, the BMQ Specific, assessing patients’ evaluations of a particular medicine for a 8 
particular condition, in this case maintenance treatment for IBD, and General, assessing 9 
patients’ evaluations of pharmaceuticals as a class of treatments.  10 
There are two BMQ Specific scales, BMQ Necessity (5-items), which assesses perceptions of 11 
need for IBD medication (e.g. ‘My life would be impossible without 12 
mesalazine/azathioprine) and BMQ Concerns (6-items), which assesses beliefs about 13 
potential adverse effects of IBD medication (e.g. ‘Having to take mesalazine/azathioprine 14 
worries me’). Participants either completed a BMQ Specific for azathioprine (AZA), or 15 
mesalamine/ (MES) or one both medication, depending on whether they were taking AZA, 16 
MES or both. Where participants completed both scales, we took their highest BMQ 17 
Concerns score and their lowest BMQ Necessity score on the basis that these scores would be 18 
indicative of barriers to adherence. A Necessity-Concerns Differential score (BMQ NCD), 19 
indexing patients’ overall evaluation of the benefits/risks of their IBD treatment was 20 
calculated by subtracting BMQ Concerns scores from BMQ Necessity scores.  21 
The BMQ General has three scales evaluating whether pharmaceutical medications are 22 
generally harmful (Harm; 5 items; e.g. ‘medicines do more harm than good’), overused and 23 
overprescribed by medical practitioners (Overuse; 3 items), or beneficial to patients and 24 
society (Benefit; 4 items).  All items are assessed on Likert type scales anchored from 25 
1=strongly agree to 5=strongly disagree. The measure has been found to be valid and reliable 26 
[33]. In the current sample, all scales had good internal reliability at baseline (Cronbach’s 27 
αs=0.74-0.91). 28 
Perceived Sensitivity to Medicines Scale (PSM). The PSM assesses perceptions of their 29 
personal sensitivity to the positive and negative effects of medicines. Participants indicate 30 
their agreement with 5 items on the same Likert-type scale as used in the BMQ. It has 31 
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previously been shown to be reliable and valid [34] and had good internal reliability at 1 
baseline in the current study (Cronbach’s α=0.90). 2 
Perceptual Barriers Profiler. In addition to the full BMQ, an IBD BMQ Specific Profiler 3 
was used to identify specific doubts and concerns about each IBD treatment. Participants 4 
were asked indicate whether they had doubts about treatment need or concerns about adverse 5 
effects by responding simply ‘yes’ or ‘no’ to doubts or concerns based on the BMQ Specific 6 
items (17 items for AZA and 17 items for MES).  7 
Practical Barriers Profiler. A scale to profile participants’ experience of practical barriers 8 
to taking medication was created by asking participants to respond ‘yes’ or ‘no’ to 10 9 
practical issues that they might experience when taking their IBD medication. For example ‘I 10 
find it difficult to remember to take my medicines when my daily routine changes’. We 11 
calculated the total number of practical barriers endorsed (possible range 0-10) as a ‘Practical 12 
Barriers’ score. 13 
The Perceptual and Practical Barriers Profilers were used to tailor the intervention content 14 
presented to participants. Participants who reported any Necessity Barriers received all the 15 
Necessity pages. Participants who reported Concerns or Practical Barriers received specific 16 
pages tailored to their individual barriers to reduce burden and ensure that barriers were not 17 
suggested to patients. For example, only participants who reported a Concern about long-term 18 
effects of treatment received information about cancer risks. All participants received access 19 
to the IBD Library. 20 
Medication Adherence Report Scale (MARS). The MARS is a validated measure of self-21 
reported adherence to IBD medication. The MARS scale [33] has been extensively used to 22 
measure self-report of the frequency of nonadherent behaviours (e.g. ‘I forget to take 23 
azathioprine’) in a variety of illness populations [31-35]. The MARS attempts to diminish the 24 
social pressure on patients to under-report non-adherence by phrasing adherence questions in 25 
a non-threatening manner. In the current study we used a 6-item version scored from 1=very 26 
often to 5=never resulting in a possible range of total scores of 6-30, 30 indicating the highest 27 
self-reported adherence. Participants completed separate scales for AZA, MES or both. For 28 
the combined analysis, we used the lowest reported score. The scale has been previously 29 
validated (e.g. [33]) and had good baseline internal reliability in for both MES (Cronbach’s 30 
α=0.80) and AZA (Cronbach’s α=0.81). 31 
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Adherence Visual Analogue Scale (VAS). Patients reported an estimate of the percentage of 1 
their AZA and/or MES medication taken over the last week on a scale from 0-100%. 2 
Brief Illness Perception Questionnaire (IPQ). The Brief IPQ [36] is an assessment of 3 
cognitive and emotional representations of illness, on eight dimensions. Patients rated their 4 
perceptions of the following aspects of their IBD: its impact on their lives (consequences), 5 
chronicity (timeline), whether they could it (personal control), whether their treatment could 6 
control it (treatment control), severity of symptoms (identity), concern about their symptoms 7 
(concern), understanding of their IBD (understanding), and distressed about their IBD 8 
(emotional response). Patients responded to each item on a scale of 0-10.  9 
Satisfaction with Information about Medicines Scale (SIMS). The SIMS [37] assesses 10 
how satisfied patients are with the information they have received about their medication. It 11 
has two subscales: SIMS Action and Usage (SIMS-AU), measuring satisfaction with 12 
information about the action and usage of IBD medication and SIMS Potential Problems 13 
(SIMS-PP) measuring satisfaction with information about the potential problems that might 14 
arise while taking IBD medication. Both scales have previously been found to be reliable and 15 
valid [37], and, in the current sample, the subscales had good internal reliability at baseline 16 
(Cronbach’s αs SIMS AU=0.81, SIMS PP=0.88).  17 
Hospital Anxiety and Depression Scale (HADS). The HADS measures current symptoms 18 
of anxiety and depression [38] on two 7-item scales. It has good reliability and validity 19 
including in IBD [35]. In the current sample both scales had good internal reliability at 20 
baseline (both Cronbach’s αs =0.83). We categorised patients as being at risk for clinically 21 
significant anxiety and depression if their total score (possible range 0-21) on either subscale 22 
was above 10 [39]. 23 
Short Inflammatory Bowel Disease Questionnaire (SIBDQ). The SIBDQ measures quality 24 
of life in IBD. It has been found to be valid, reliable and sensitive to clinical changes 25 
(Cronbach’s α=0.87 in current study). [36] The scale has 10 items that are summed to form a 26 
total score (range 10-70) with higher scores indicative of better health.  27 
Demographic and clinical information. Participants reported demographic factors: their 28 
date of birth, gender, marital status, level of education, and ethnicity. They also reported 29 
clinical information: age when diagnosed with IBD, whether they were currently in remission 30 
or having a flare-up, number of flare-ups experienced in the last 3 months, medications 31 
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prescribed for IBD, and number of consultations for IBD (planned and unplanned) with 1 
healthcare professionals in the last 3 months. 2 
Acceptability and Usage Assessments 3 
We conducted quantitative and qualitative assessments of the acceptability of the 4 
intervention. We also assessed intervention usage by evaluating which participants had 5 
logged in, for how long, and to which sections of the website.  6 
Quantitative Assessment- Acceptability Questionnaire. After completing, the final 3-7 
month follow-up participants in the Intervention Group were automatically emailed a link to 8 
a brief, final questionnaire evaluating the intervention. This included 17 statements about the 9 
functionality, usefulness and trustworthiness of the website e.g. ‘I think the information on 10 
this website was not convincing’, which participants rated their agreement with on a 5-point 11 
Likert-type scale (1=strongly agree, 5=strongly disagree). 12 
Qualitative Assessment-Acceptability Interviews. When giving informed consent, 13 
participants were asked if they would be willing to be contacted for a follow-up telephone 14 
interview. After recruitment and follow-up was complete, we contacted participants who had 15 
expressed interest in this who were in the Intervention Group. We purposively sampled 6 16 
male and female participants who had and hadn’t used the intervention. Two research 17 
assistants trained in qualitative methods conducted telephone interviews using a semi-18 
structured interview schedule to explore experiences of the intervention. The interviews were 19 
transcribed and themes and quotes from the interviews are used below to provide context to 20 
the quantitative data collected [41].  21 
Intervention Usage Statistics. The platform automatically recorded the time each page of 22 
the Intervention site was accessed. Using this information, we were able to calculate the total 23 
time spent accessing the website by each participant and check when the intervention content 24 
was accessed over the follow-up period (i.e. total number of visits to the intervention, total 25 
time spent across intervention, date of first access). 26 
Statistical Analysis and Sample Size Calculation 27 
We determined the sample size needed to obtain 80% power to detect a statistically 28 
significant (p≤.05) medium-sized difference (Cohen’s d=0.5) in beliefs between Control and 29 
Intervention Groups at follow-up using the statistical package G*Power 3.1.3 (® Dusseldorf), 30 
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based on effect sizes for other online interventions [37]. We estimated 128 participants (64 1 
per group) were necessary, rising to 214 assuming a 40% drop-out rate.  2 
Statistical analysis was undertaken using SPSS 21 (®, IBM). We used intention-to-treat 3 
analysis (i.e. without excluding participants who did not access the intervention) to assess the 4 
unbiased effect of the intervention. We tested for normality of our variables and used means 5 
and standard deviations to describe normally distributed variables, and medians and 6 
interquartile ranges to describe skewed variables. At baseline, 1 month and 3 months follow-7 
up we tested for between-group differences in each variable using t-tests with Levene’s 8 
adjustment for unequal distributions or Mann-Whitney U-tests as appropriate.  9 




Recruitment and Retention 2 
The screening questionnaire was completed by 1267 potential participants, 1115 of whom 3 
met the eligibility criteria, 381 participants consented to take part in the study and started the 4 
baseline questionnaire. See Figure 1 for recruitment and retention. Over 300 patients (329) 5 
were allocated to intervention or control. At 3 months follow-up, just 46.2% of participants 6 
were retained in the study. 7 
Sample demographics  8 
The sample was 72.8% female (n=238). Participants were aged between 18.5 years and 73.0 9 
years, the median age was 36.3 years. The sample was 89.3% White British (n=293). One 10 
hundred and fifty six participants had obtained a degree or higher degree (47.7%). 11 
Baseline clinical status  12 
At baseline, 54.3% of participants reported that they were currently experiencing a mild to 13 
moderate flare-up (n=117) and 35.7% were in remission (n=117) and the remainder reported 14 
a current severe flare-up (n=33, 10.1%). The median number of flare-ups reported by 15 
participants in the previous 3 months was 1 (range 0-31), with 75.2% of participants reporting 16 
at least one recent flare-up. Healthcare seeking for IBD was not high; most participants 17 
reported 1 or fewer GP, consultant, nurse, telephone helpline, or pharmacist contacts. 72.9% 18 
of participants were taking mesalamine and 54.7% were taking azathioprine. See Table 2 for 19 
statistics. 20 
The mean HADS anxiety score was 9.9 (SD=4.3). The mean HADS depression score was 7.5 21 
(SD=2.2). Overall, 133 participants (41.8%) scored above 10 for HADS anxiety, and 70 22 
(21.5%) scored above 10 for HADS depression, indicating risk of clinical significance.  23 
Primary outcome: Perceptual and practical barriers to adherence 24 
Participants reported both perceptual and practical barriers to taking their IBD medication at 25 
baseline. On the profiling scale 90.8% (n=267) of participants reported at least one concern 26 
about their medication, 95.4% (n=312) had at least one doubt about whether their IBD 27 
medication was needed, and 89.9% (n=295) had at least one practical barrier to taking their 28 
IBD medication.  29 
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Pre-intervention, participants in the Intervention and Control Groups reported similar levels 1 
of concerns about their medication (BMQ Specific Concerns), and doubts about necessity 2 
(BMQ Specific Necessity). We split participants into those who reported high and low 3 
concerns and necessity beliefs using the midpoint of the scales (as per [16]). At baseline, 4 
30.5% (n=99) of participants reported significant doubts about their need for their IBD 5 
medication (low BMQ Specific Necessity), and 43.3% (n=141) reported high concerns about 6 
the potential adverse effects of their IBD medication (high BMQ Specific Concerns). 7 
Descriptive statistics for BMQ Necessity, BMQ Concerns, and the difference between these 8 
two scores are presented in Table 3.   9 
Specific beliefs at follow-up 10 
At both 1 and 3 months follow-up, the Intervention Group had a higher BMQ NCD score, 11 
indicating that their belief in their personal need for medication tended to outweigh their 12 
concerns to a greater extent than it did for the Control Group, and this was statistically 13 
significant at 3 months. They also expressed statistically significantly fewer doubts about 14 
their personal need for IBD medication at 3 months, and fewer concerns about the potential 15 
adverse effects of IBD medication at 1 and 3 months (see Table 3 and Figure 2). 16 
Practical barriers to taking medication at follow-up 17 
Intervention Group participants reported fewer practical barriers to taking medication at both 18 
follow-up time points, but this was only statistically significant at 3 months (see Table 3). 19 
Secondary Outcomes 20 
See Tables 4 & 5 for descriptive statistics and between-group comparisons. 21 
Adherence  22 
Reported adherence to medication was high; at baseline the median MARS score was 28 23 
(range 10-30) and the median VAS adherence was 100% (range 0-100).  Likewise at both 24 
follow-ups, the median VAS score was 100% in both groups for both medications. Due to 25 
highly skewed data, we used non-parametric tests, to assess whether mean ranks of adherence 26 
scores were different between the Intervention and Control groups over follow-up. At 1- and 27 
3-months post-intervention the Intervention Group had higher VAS adherence than Controls, 28 
higher adherence to mesalamine alone at 1 month on the VAS, and higher adherence to 29 
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azathioprine on both VAS and MARS at 3 months. There were no statistically significant 1 
differences between groups for MARS adherence to mesalamine. 2 
Satisfaction with information about IBD medication 3 
At baseline participants reported that they were satisfied with a mean of 7.01 SIMS items 4 
about Action and Usage (of a total of 9) and 4.82 SIMS items about the Potential Problems 5 
associated with their medication (of a total of 8). There were no differences between the 6 
Intervention and Control Groups in terms of satisfaction with information at baseline. 7 
Intervention Group participants were more satisfied with the information they had received 8 
about the potential problems associated with IBD medication (SIMS PP) than Controls at 9 
both follow-up points (p < .05). Intervention participants were also more satisfied with the 10 
information they had received about the action and usage of medication (SIMS AU) at both 11 
follow-up points, but this was only statistically significant at 1 month (p < .05). 12 
General beliefs about pharmaceuticals as a class of treatment 13 
The groups were not statistically significantly different on general beliefs about 14 
pharmaceutical medication: BMQ Harm, BMQ Overuse, BMQ General Benefit and 15 
Perceived Sensitivity to Medicines at baseline. The Intervention Group were less likely than 16 
Controls to believe that pharmaceutical medication is generally overused (BMQ Overuse) 17 
and harmful (BMQ Harm) at both 1 month and 3 months follow-up (p< .05). There were no 18 
statistically significant effects at either time on the belief that medications are generally 19 
beneficial (BMQ Benefit) or on patients’ perceptions of their own sensitivity to the effects of 20 
medications (PSM). 21 
Illness beliefs 22 
Participants’ scores on the Brief IPQ at baseline indicated that participants felt their IBD was 23 
fairly severe, chronic, distressing and concerning but relatively well understood (see 24 
Supplementary material for individual item scores. There was no overall difference in 25 
baseline brief IPQ scores but a small statistically significant difference between groups at 26 
baseline in treatment control beliefs; patients in the Intervention Group reported slightly more 27 
agreement that their treatment can control their IBD than participants in the Control Group. 28 
Participants in the Intervention Group had viewed their IBD more positively than Controls at 29 
1 and 3 months although this was only statistically significant at 1 month (see Table 3). 30 
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Quality of life, Anxiety and Depression 1 
Participants in the Intervention Group reported less anxiety and depression than controls 2 
(HADS Anxiety and HADS Depression scales) and higher IBD-related quality of life 3 
(SIBDQ) at both follow-up points. However, the differences between groups were only 4 
statistically significant for anxiety and depression at the 3-month follow-up. See Table 3 for 5 
means, medians and t-tests. 6 
Acceptability Questionnaire and Interviews 7 
Analysis of the acceptability interviews is presented in the Appendix. Thirty-two participants 8 
in the Intervention Group filled in the acceptability questionnaire. The website was rated as 9 
‘easy to understand’ by 100% (n=32) of participants and ‘easy to navigate’ by 93.3% (n=28) 10 
of participants. A small number of participants indicated they found the website slow to load 11 
(n=4, 13.3%) and unattractive (n=6, 20.0%).  Most participants disagreed or strongly 12 
disagreed that the website ‘took too long’ 84.4% (n=27), was ‘not relevant to me’ 75.0% 13 
(n=24), ‘not believable’ 87.5% (n=28), and ‘not convincing’ 84.4% (n=27), indicating 14 
positive views of the website.  Likewise, 56.3% (n=18) agreed or strongly agreed that the 15 
cartoons were helpful, 62.5% (n=20) were happy with the number of questions on the 16 
website, and 59.4% (n=19) thought the website had made them think.  Perceptions of the 17 
intervention team were positive; the majority of the respondents rated the team as ‘credible’ 18 
(86.7% n=26), ‘trustworthy’ (83.3%, n=25), ‘dependable’ (76.7%, n=23), ‘reliable’ (73.3%, 19 
n=22), and ‘reputable’ (83.3%, n=25).  20 
Intervention Usage 21 
The intervention was used by 73.2% (n=112) of the Intervention Group. Of participants who 22 
logged on to the intervention, the maximum number of sessions was 5 and slightly over half 23 
of participants (54.9%, n=84) logged on once with the remaining participants using the 24 
intervention on multiple occasions. The total time spent on the website varied between <0.01 25 
seconds and 73 minutes, (median = 9.36 minutes). Participants accessed a median of 22 pages 26 
(range 1-124).  27 
Forty-one participants (26.8%) in the Intervention Group never logged on to the intervention. 28 
There were no differences between participants who logged on to the intervention and those 29 
who did not in terms of demographic variables (age, gender, ethnicity or education level), 30 
baseline specific beliefs about medication for IBD (Specific Necessity and Concerns), 31 
18 
 
baseline general beliefs about medications (Harm, Overuse, Benefits), perceived personal 1 
sensitivity to medicines, illness beliefs (IPQ), anxiety, depression or self-reported adherence 2 
(all p > .05).  3 
The most frequently visited area of the website was the Practical Barriers section, which 4 
75.9% (n=85) of participants used. The Concerns section was accessed by 56.3% (n=63), the 5 




This is the first study to evaluate an intervention to change adherence-related beliefs about 2 
maintenance treatment for IBD. We found a clear need for the intervention; all potential 3 
participants reported a some doubt about the personal necessity of medication, concern about 4 
medicines, or practical barrier to adherence. There was evidence the intervention effectively 5 
addressed these barriers.  6 
Perceptual and practical barriers have been associated with adherence in IBD [14-16]. From 7 
equivalence at baseline, intervention participants had statistically significantly stronger 8 
beliefs in the Necessity of their medication at 3-months follow up relative to the Control 9 
group. This was achieved by providing patients with a common-sense rationale for 10 
treatmentand using the Persignia3 algorithm . The intervention reduced concerns about 11 
medication over time relative to the Control Group.  12 
There were other indicators of efficacy on secondary outcomes. Intervention Group 13 
participants reported more satisfaction with information about IBD medication, more positive 14 
beliefs about medications in general, and more positive views of IBD than the Control Group 15 
at follow-up. This suggests addressing barriers to adherence may affect multiple variables 16 
relevant to IBD self-management. The acceptability questionnaire recorded largely positive 17 
views of the intervention. Participant interviews indicated the content was useful and 18 
trustworthy, and suggested areas for further development including technical issues relating 19 
to the web-based delivery channel. Intervention usage statistics indicated most participants 20 
spent less than 15 minutes using the intervention. The online PAPA-based intervention has 21 
the capacity to modify adherence barriers, is likely to be acceptable to patients and feasible to 22 
deliver. 23 
The effect of the intervention was less robust on other variables. Relative to Controls, 24 
Intervention Group participants reported fewer practical barriers at 1 and 3 months follow-up, 25 
this difference was only statistically significant at 3 months. The lack of change in practical 26 
barriers could indicate a need for face-to-face or other support to address practical factors 27 
such as difficulty in obtaining prescriptions or regimen complexity. Self-reported adherence 28 
was higher in the Intervention Group at 1 month and 3 months follow-up but this was only 29 
                                                          
3  Working title 
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statistically significant for the VAS measure at 3 months. These differences are small and 1 
unlikely to affect clinical outcomes in the short term, however, over time, not addressing 2 
barriers to adherence may increase vulnerability to nonadherence and subsequently flare-ups 3 
and hospitalisations. We found higher levels of reported adherence than previously reported 4 
in IBD [2, 5-10], perhaps indicating our participants were more highly engaged with their 5 
care than is typical, or that they under-reported nonadherence which may have placed a 6 
ceiling effect on improvements in adherence.  7 
Usage statistics indicated that patients varied in their use of the intervention, with some using 8 
the intervention for a single short visit and others returning several times to the resources. 9 
Overall, the median intervention usage time was under 10 minutes, indicating that it can be 10 
considered to be low intensity relative to traditional face-to-face interventions that require a 11 
series of appointments. Post-intervention questionnaires indicated that the intervention 12 
content, website function and perceptions of the intervention source were largely positive. 13 
Most participants who completed the feedback scale rated the website content as useful, the 14 
research team as reliable and expert, and the loading of the website was not too slow. It 15 
appears therefore that the intervention was largely acceptable to participants.  16 
Limitations  17 
Although our findings are promising and provide ‘proof of principle’ that tailored messages 18 
can change adherence-related beliefs, the efficacy of the approach needs to be further tested 19 
in a full scale RCT. Several limitations of trial design and conduct mean that the current 20 
results do not represent a full test: allocation was blind but not fully randomised, high dropout 21 
rates, and the monetary stimulus may also have biased the results of this pilot [38-40]. Our 22 
attrition rate is typical of internet-based trials [41]. Perhaps the initial decision to participate 23 
online requires less engagement, meaning participants are more prone to drop-out. Internet-24 
based trials are more ‘pragmatic’ and typical of practice than clinical trials e.g. our high drop-25 
out rate may parallel poorer attendance at follow-up appointments when patients are 26 
recovered, however we cannot evaluate this using our data. We only have self-reported 27 
prescriptions, clinical and adherence data, up to 3 months follow-up, limiting 28 
recommendations regarding use of the intervention in practice. [42] The study was not 29 
powered to determine effects on flare-ups or healthcare seeking. Finally, our participants may 30 
represent a subset of relatively highly engaged IBD patients and therefore these findings may 31 
not generalise.  32 
21 
 
Implications for clinicians and policymakers 1 
Despite these limitations, these findings suggest that management of IBD may be improved 2 
by providing online support to patients to address their personal barriers to adherence. Our 3 
results indicate that directly addressing patients’ doubts about treatment need and concerns 4 
about adverse effects is possible, that it need not be highly time-consuming and that this 5 
could impact positively on self-management as an addition to current clinical practice. Online 6 
resources providing such personalised information may therefore be a useful addition to 7 
existing models of care. This could be explored further in different healthcare settings (e.g. 8 
resource limited settings,) and for different treatment regimens (e.g. steroids and biologics). 9 
While we focused on mesalazine and azathioprine, patients also have concerns about new 10 
biologic therapies, suggesting a similar intervention may support adherence to these drugs 11 
[43]. 12 
Conclusion 13 
A PAPA-based intervention changed adherence-related medication necessity beliefs and 14 
concerns. Online interventions providing tailored information addressing barriers to 15 
medication taking may be an acceptable and feasible tool for supporting IBD patients to 16 
adhere to treatment. Potentially, this intervention may reduce flare-ups, hospital admissions 17 
and other clinical indicators, however full trials are needed to evaluate this. These findings 18 
suggest that a brief, online PAPA-based intervention has the capacity to support adherence, is 19 
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Figure Legends 1 
Figure 1: Participant flow chart  2 
Note: AZA = participants taking azathioprine, MES = participants taking mesalamine, 3 
AZA+MES = participants taking both azathioprine and mesalamine. 4 
*371 started baseline measures but of these, 42 participants dropped out before completing 5 
baseline. 6 
Figure 2: Mean BMQ Necessity and Concern beliefs at baseline and follow-up 7 
Note: BMQ = Beliefs about Medicines Questionnaire Necessity and Concerns scores, NCD = 8 
Necessity Concerns Differential 9 




Table 1: Sample Demographics 2 





Gender: n(%) female 111 (72.5%) 127 (72.2%) 
Ethnicity: n(%) White British 137 (89.5%) 156 (88.6%) 
Age in years: Median [IQR] 36.0 [27.9-47.1] 36.8 [28.7-45.1] 
Education: n(%) with degree/higher degree 76 (49.7%) 80 (46.0%) 
Marital status: n(%) married/civil partnership/cohabiting 94 (61.4%) 100 (56.8%) 
  4 
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Table 2: Clinical descriptive statistics 1 





Current reported IBD status n(%)   
 … in remission 57 (37.3%) 60 (34.3%) 
 …mild to moderate flare-up 82 (53.6%) 96 (54.9%) 
 …severe flare-up 14 (9.2%) 19 (10.8%) 
   
Last 3 months, number of...  median[IQR]   
flare-ups 1 [0-2] 1 [1-2] 
flare-ups leading to change in treatment  0 [0-1] 0 [0-1] 
face-to-face GP consultations 1 [0-2] 1 [0-3] 
planned face-to-face GP consultations 0 [0-1] 0 [0-1] 
face-to-face IBD consultant consultations 1 [0-2] 1 [0-2] 
planned face-to-face IBD consultant consultations 1 [0-1] 1 [0-1] 
face-to-face IBD nurse consultations 0 [0-1] 0 [0-0] 
telephone/email contacts with IBD nurse 0 [0-3] 0 [0-3] 
IBD nurse helpline contacts 0 [0-1] 0 [0-1] 
face-to-face consultations with hospital/retail pharmacist 0 [0-1] 0 [0-1] 
Current prescription n(%)   
  Mesalamine  112 (73.2%) 128 (72.7%) 
  Azathioprine 82 (53.6%) 98 (55.7%) 
  Mercaptopurine 3 (2.0%) 10 (5.7%) 
  Prednisolone 40 (26.1%) 44 (25.0%) 
  Budesonide 8 (5.2%) 10 (5.7%) 
  Hydrocortisone 3 (2.0%) 10 (5.7%) 
  Infliximab 10 (6.5%) 13 (7.4%) 
  Adalimumab 14 (9.2%) 11 (6.3%) 




Table 3: Means, standard deviations and group comparisons (t-tests) for primary outcomes  























 m (SD) m (SD) p m (SD) m (SD) p m (SD) m (SD) p 
BMQ Concerns 2.86 (0.77) 2.94 (0.80) .39 2.61 (0.86) 2.90 (0.84) .01 2.52 (0.77) 2.98 (0.79) <.01 
BMQ Necessity 3.26 (0.92) 3.21 (0.91) .57 3.20 (1.05) 3.20 (0.93) .96 3.39 (1.01) 2.94 (1.03) .02 
BMQ NCD 0.40 (1.11) 0.26 (1.12) .27 0.59 (1.21) 0.30 (1.20) .07 0.87 (1.24) -0.03 (1.18) <.001 
Practical Barriers 3.58 (2.67) 3.50 (2.49) .78 3.19 (3.15) 3.50 (2.80) .43 2.18 (2.29) 3.25 (2.77) .03 
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Table 4: Descriptive statistics m(SD) or median [interquartile range] and group comparisons for secondary outcomes  
Notes: All comparisons t tests except for MARS and VASA where Mann-Whitney U results reported; IG=Intervention Group, CG=Control 
Group, MARS = Medication Adherence Report Scale, VASA = Adherence VAS, BMQ = Beliefs about Medicines Questionnaire, PSM = 
Perceived Sensitivity to Medicines Scale, HADS = Hospital Anxiety and Depression Scale, SIBDQ = Short Inflammatory Bowel Disease 
Questionnaire, SIMS AU = Satisfaction with Information about Medicines Action and Usage Subscale, SIMS PP = Satisfaction with Information 
about Medicines Potential Problems Subscale.  Brief Illness Perception Questionnaire results in Supplementary Content. 














MARS 28 [24-30] 28 [25-30] .97 29 [25-30] 28 [25-30] .55 29 [27.3-30] 28.5 [25-30] .10 
VASA 100 [90-100] 100 [90-100] .57 100 [90-100] 100 [90-100] .23 100 [90-100] 100 [90-100] .03 
BMQ Harm 2.22 (0.68) 2.23 (0.66) .92 2.11 (0.79) 2.30 (0.66) .05 1.99 (0.57) 2.26 (0.61) .02 
BMQ Overuse 2.74 (0.88) 2.87 (0.86) .19 2.67 (0.95) 3.03 (0.88) <.01 2.62 (0.69) 3.07 (0.90) <.01 
BMQ Benefit 3.97 (0.54) 3.89 (0.64) .25 3.97 (0.53) 3.91 (0.53) .34 3.93 (0.48) 3.88 (0.46) .63 
PSM 2.80 (0.94) 2.83 (0.92) .73 2.74 (1.03) 2.84 (0.91) .40 2.86 (1.06) 2.82 (0.91) .85 
HADS Anxiety 9.79 (4.41) 9.97 (4.18) .71 8.61 (4.91) 9.63 (4.52) .11 7.26 (4.87) 9.53 (3.99) <.01 
HADS Depression 7.47 (4.23) 7.57 (4.21) .84 6.70 (4.71) 7.69 (4.52) .11 5.74 (4.10) 7.08 (4.09) <.01 
SIBDQ 38.01 (11.22) 36.91 (12.46) .41 41.77 (13.19) 39.60 (13.47) .23 44.15 (12.59) 41.11 (11.87) .18 
SIMS AU 7.08 (2.28) 6.94 (2.11) .58 7.90 (2.19) 7.27 (2.27) .03 7.52 (2.35) 8.27 (2.32) .09 
SIMS PP 4.97 (2.54) 4.69 (2.49) .32 5.79 (2.51) 5.02 (2.61) .03 7.04 (2.23) 5.27 (2.67) <.001 
Brief IPQ 55.19 (7.38) 55.27 (8.15) .92 53.16 (7.51) 55.17 (7.68) .04 52.65 (8.78) 54.76 (8.58) .20 
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